摘要
To the Editor:Immune checkpoint inhibitors(ICIs)interact with critical factors involved in immunoregulation.Following the FDA approval of nivolumab as a second line therapy for unresectable hepatocellular carcinoma(HCC)in 2017,numerous HCC patients have experienced benefits from ICIs[1].In 2020,the FDA approved the combination of atezolizumab and bevacizumab as first line treatment for unresectable HCCs that have not undergone prior systemic treatments[2].ICIs are driving a transformative change in the field of cancer therapy.
